Clopidogrel: The good, the bad, and the ugly

American Journal of Cardiovascular Drugs

Volumn 7, Issue 3, 2007, Pages 169-171

  Chow, Grant ^a   Ziegelstein, Roy C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; NOTE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; TICLOPIDINE;

EID: 34447315050     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707030-00003     Document Type: Note

References (23)

1. Angioplasty.Org. Current news: generic version of Plavix® (clopidogrel) is launched by Apotex [online]. Available from URL: http://www.ptca.org/new-scenter.html?.http://www.ptca.org/news/2006/0808.html [Accessed 2007 Jan 26]
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-74
3. Collins JS, Gurm HS. Increasing use of clopidogrel in revascularized and non-revascularized patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7 (3): 159-68
4. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005; 142: 251-9
5. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800-6
6. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998; 20: 764-71
7. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006; 12 Spec no: SP11-9
8. Cole JA, Norman H, Weatherby LB, et al. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 2006; 26: 1157-64
9. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-9
10. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
11. Ziegelstein RC. Clopidogrel in patients with acute coronary syndromes: learning from clinical practice. Arch Intern Med 2006; 166: 2292-3
12. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056-61
13. Morice MC, Serruys PW, Sousa JE, et al., on behalf of the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80
14. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056-61
15. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al., for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-91
16. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-68
17. Grines CL, Bonow RO, Casey Jr DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115 (6): 813-8
18. Shuchman M. Delaying generic competition: corporate payoffs and the future of Plavix. N Engl J Med 2006; 355: 1297-300
19. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
20. Calvin JE, Roe MT, Chen AY, et al. Insurance coverage and care of patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2006; 145: 739-48
21. Budaj A, Flasinska K, Gore JM, et al. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation 2005; 111: 3242-7
22. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-23
23. American Heart Association. Heart Disease and Stroke Statistics: 2007 update. Dallas (TX): American Heart Association, 2007